• Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    Source: Buzz FX / 23 Apr 2024 01:36:19   America/New_York


    Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
    Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
    Rilzabrutinib LUNA 3 phase 3 study met prima
    Read more...
Share on,